We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Bifunctional Anticancer Nanoparticles Deliver a Drug and Then Report Whether It Works

By LabMedica International staff writers
Posted on 11 Apr 2016
Print article
Image: Using reporter nanoparticles loaded with either a chemotherapy or immunotherapy, researchers could distinguish between drug-sensitive and drug-resistant tumors in a pre-clinical model of prostate cancer (Photo courtesy of Dr. Ashish Kulkarni, Brigham and Women\'s Hospital).
Image: Using reporter nanoparticles loaded with either a chemotherapy or immunotherapy, researchers could distinguish between drug-sensitive and drug-resistant tumors in a pre-clinical model of prostate cancer (Photo courtesy of Dr. Ashish Kulkarni, Brigham and Women\'s Hospital).
A novel nanoparticle-based transport system not only delivers an anticancer agent to a tumor, it reports whether the treatment is working.

The ability to monitor the efficacy of an anticancer treatment in real time can have a critical effect on the patient's outcome. Currently, determination of a treatment's effectiveness relies on indirect or anatomic measurements, which occur over prolonged time scales and follow chemotherapy, radiotherapy, or immunotherapy and may not accurately reflect the actual effect.

Investigators at Brigham and Women's Hospital (Boston, MA, USA) recently described a new approach for evaluating the effectiveness of cancer treatment early in the therapeutic effort.

Their method utilizes bifunctional nanoparticles that delivered both an anticancer agent and a fluorescent reporter mechanism to the tumor. The reporter system was based on the activation of the enzyme caspase that occurred when cancer cells began to die. Caspase that was released when the transported drug was successful caused the reporter molecule to emit green fluorescence, which was detected easily with a microscope.

Using chemotherapy-sensitive and chemotherapy-resistant tumors in vivo, the investigators showed that the reporter nanoparticles could provide a real-time noninvasive readout of tumor response to chemotherapy.

They reported in the March 29, 2016, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that in a preclinical model of prostate cancer, nanoparticles loaded with the anticancer drug paclitaxel caused a 400% increase in fluorescence in sensitive cells compared to cells in tumors that were not sensitive to the drug. The increase in fluorescence was apparent about eight hours after beginning the treatment.

In an immunotherapy approach that employed nanoparticles to target PD-L1 (Programmed cell death protein ligand 1) in a preclinical model of melanoma, the investigators found a significant increase in the fluorescent signal after five days.

"Using this approach, the cells light up the moment a cancer drug starts working. We can determine if a cancer therapy is effective within hours of treatment," said senior author Dr. Shiladitya Sengupta, assistant professor of health sciences and technology at Brigham and Women's Hospital. "Our long-term goal is to find a way to monitor outcomes very early so that we do not give a chemotherapy drug to patients who are not responding to it."

Related Links:

Brigham and Women's Hospital


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.